CAMBRIDGE, Mass., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its President and CEO, Robert Ward, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 2:00 p.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York.
The presentation will be webcast live on the Company's website at www.radiuspharm.com. A replay of the webcast will be available on the Company's website following the presentation. The Company will post a copy of the presentation materials on its website, www.radiuspharm.com, prior to the start of the presentation.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.comSource:Radius Health